Loading market movers...

All Therapeutic Areas

🛡️

Immunology & Inflammation

94 drugs in pipeline from 10 companies

94

Drugs in Pipeline

10

Companies

4

Upcoming Catalysts

94

Phase 3 Trials

Upcoming Catalysts

Oct '26

NVSPhase 3$271.5B

ianalumab Phase 3 Est. Readout

Ianalumab• Warm Autoimmune Hemolytic Anemia (wAIHA)226

Oct 2026~Estimated

00%

Oct '26

RHHBYPhase 3$351.3B

Afimkibart Phase 3 Est. Readout (Ametrine-2)

Afimkibart• Crohns Disease350

Oct 2026~Estimated

00%

Oct '26

MAAT.PAPhase 2$27M

Pooled allogeneic fecal microbiotherapy Phase 2 Est. Readout

Pooled allogeneic fecal microbiotherapy• Transplant Complication387

Oct 2026~Estimated

00%

Oct '26

TEVAPhase 3$46.0B

TEV-56248 Phase 3 Est. Readout

TEV-56248• Asthma2,772

Oct 2026~Estimated

00%

View all catalysts

Pipeline by Phase

Phase 3

94

Active Companies

Novartis AG

Regeneron Pharmaceuticals, Inc.

PFIZER

PharmaMar, S.A.

Merck KGaA

Amgen Inc.

IQVIA HOLDINGS INC.

MERCK

HeartSciences Inc.

Organon & Co.

Related Conditions

autoimmunerheumatoid arthritislupuspsoriasiscrohnulcerative colitisibdinflammatoryimmuneimmunologyeczemadermatitisankylosing spondylitismultiple sclerosisgrafttransplantrejectionallergyasthma